Bioton SA operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Bioton SA with three other
pharmaceutical manufacturers in Europe:
COSMO Pharmaceuticals SA
sales of 67.66 million Euro [US$79.42 million]
of which 53%
was Manufacturing of MMX Products),
Solon Eiendom ASA
(691.50 million Norwegian Kroner [US$82.86 million]
of which 114%
was Residential Real Estate), and
Bosnalijek d.d. Sarajevo
based in Bosnia
(135.81 million Bosnian Convertible Marks [US$81.92 million]
During the year ended December of 2016, sales at
Bioton SA were 277.61 million Polish New Zlotys (US$77.42 million).
decrease of 31.4%
versus 2015, when the company's sales were 404.41 million Polish New Zlotys.
The sales level in 2016 was fairly close to the level five years ago: in 2011, Bioton SA had sales
of 288.98 million Polish New Zlotys.
Contributing to the drop in overall sales was the 10.0% decline
in Insulin (Bioton Sa), from 183.59 million Polish New Zlotys to 165.26 million Polish New Zlotys.
However, these declines were partially offset by the increase in sales of
Scigen Group (up 29.0% to 111.75 million Polish New Zlotys)
Biolek (up 1,417.5% to 607,000.00 Polish New Zlotys)